<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a variant proportion of patients presenting with <z:hpo ids='HP_0100749'>chest pain</z:hpo> and <z:hpo ids='HP_0011675'>electrocardiographic changes</z:hpo> charactheristic for ST - elevation <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, percutaneous coronary intervention achieve epicardial coronary artery reperfusion but not myocardial reperfusion (ranging from 5% to 50%); furthermore, prolonged <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> often breaks down the coronary microvasculature and the flow to the <z:mpath ids='MPATH_124'>infarct</z:mpath> myocardium may be markedly reduced </plain></SENT>
<SENT sid="1" pm="."><plain>This condition is known as no reflow - phenomenon </plain></SENT>
<SENT sid="2" pm="."><plain>The no reflow - phenomenon is associated with an increased incidence of malignant <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, <z:hpo ids='HP_0001635'>heart failure</z:hpo> and 30-days mortality </plain></SENT>
<SENT sid="3" pm="."><plain>In the recent years in literature several articles (subsequently discussed in the present review) have been published and made relevant to the study of the pathophysiology of no reflow - phenomenon; such knowledge has helped the development of new treatment strategies such as prophylactic use of <z:chebi fb="1" ids="35620">vasodilators</z:chebi>, mechanical devices and drugs inhibiting platelet </plain></SENT>
<SENT sid="4" pm="."><plain>The aim of this review is to analyze the current literature about intra - coronary injection of drugs to treat no - reflow and microvascular dysfunction </plain></SENT>
</text></document>